Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

doi:10.1056/NEJMoa1604958

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

The New England journal of medicine - 1 Sept 2016

Zaretsky Jesse M, Garcia-Diaz Angel, Shin Daniel S, Escuin-Ordinas Helena, Hugo Willy, Hu-Lieskovan Siwen, Torrejon Davis Y, Abril-Rodriguez Gabriel, Sandoval Salemiz, Barthly Lucas, Saco Justin, Homet Moreno Blanca, Mezzadra Riccardo, Chmielowski Bartosz, Ruchalski Kathleen, Shintaku I Peter, Sanchez Phillip J, Puig-Saus Cristina, Cherry Grace, Seja Elizabeth, Kong Xiangju, Pang Jia, Berent-Maoz Beata, Comin-Anduix Begoña, Graeber Thomas G, Tumeh Paul C, Schumacher Ton N M, Lo Roger S, Ribas Antoni

Abstract excerpt

BACKGROUND: Approximately 75% of objective responses to anti-programmed death 1 (PD-1) therapy in patients with melanoma are durable, lasting for years, but delayed relapses have been noted long after initial objective tumor regression despite continuous therapy. Mechanisms of immune escape in this context are unknown. METHODS: We analyzed biopsy samples from paired baseline and relapsing lesions in four patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to beta 2-Microglobulin

Share to Genes, MHC Class I

Share to Immunotherapy

Share to Interferon-gamma

Share to Janus Kinase 1

Share to Janus Kinase 2

Share to Programmed Cell Death 1 Receptor

Source

Open in PubMed Open full text

Identifiers

PMID: 27433843
DOI: 10.1056/NEJMoa1604958
PMCID: PMC5007206

Genes

JAK1
JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.PMID 27433843Read ↗

Resistance to checkpoint blockade therapy through inactivation of antigen presentationSemantic proximity Read ↗

Unmasking PD-1 Resistance by Next-Generation SequencingSemantic proximity Read ↗

Molecular patterns of resistance to immune checkpoint blockade in melanomaSemantic proximity Read ↗

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.Semantic proximity Read ↗

Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.Semantic proximity Read ↗

Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An UpdateSemantic proximity Read ↗

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint BlockadeSemantic proximity Read ↗

The molecular and functional landscape of resistance to immune checkpoint blockade in melanomaSemantic proximity Read ↗

Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma.Semantic proximity Read ↗

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.Semantic proximity Read ↗

Genetic basis for clinical response to CTLA-4 blockade in melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.